Literature DB >> 34242901

MIF-mediated NF-κB signaling pathway regulates the pathogenesis of polycystic ovary syndrome in rats.

Zhenlin He1, Yuelong Wang2, Li Zhuan3, Yunxiu Li3, Z-Ouyin Tang3, Ze Wu3, Yanping Ma4.   

Abstract

Polycystic ovary syndrome (PCOS) resulting from abnormal glucose metabolism is a relatively common and complex endocrine disorder among women in their reproductive years, However, the pathogenesis of PCOS is still unclear. The purpose of this study is to investigate the macrophage migration inhibitory factor (MIF) involvement of the nuclear factor (NF)-κB in rats with PCOS. Results indicated that testosterone promoted the increase in the levels of MIF and luteinizing hormone (LH) but inhibited the increase in the level of follicular stimulating hormone (FSH). The MIF antibody could alleviate the process of PCOS to a certain extent. Testosterone promoted the expression of interleukin 1-beta (IL-1β), interleukin 6 (IL-6), Inducible nitric oxide synthase (iNOS), and tumor necrosis factor alpha (TNF-α); the MIF antibody could reverse this effect. Testosterone could inhibit the expression of NF-κB protein whereas MIF antibody could promote the expression in the ovarian cytoplasm. Testosterone promoted the expression of NF-κB protein in the nucleus, this effect also could be reversed by the MIF antibody. Hyperandrogenism activated the NF-κB pathway. After using the MIF antibody, this effect was reversed. This finding suggested that hyperandrogenism activated the NF-κB pathway through MIF. In short, increased MIF levels activated the NF-κB pathway in ovaries, leading to inflammation and the increase in the levels of relevant inflammatory indicators, which might be one of the important factors in the pathogenesis of PCOS.
Copyright © 2021 The First People¼s Hospital of Yunnan. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Androgen; Inflammatory cytokines; Migration inhibitory factor; NF-κB signaling pathway; Polycystic ovary syndrome; Testosterone

Mesh:

Substances:

Year:  2021        PMID: 34242901     DOI: 10.1016/j.cyto.2021.155632

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  5 in total

1.  Integrated Network Pharmacology and Clinical Study to Reveal the Effects and Mechanisms of Bushen Huoxue Huatan Decoction on Polycystic Ovary Syndrome.

Authors:  Jie Ding; Mei Shanshan; Cai Mengcheng; Zhang Danying; Yu Jin
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

2.  Modified Banxia Xiexin Decoction Ameliorates Polycystic Ovarian Syndrome With Insulin Resistance by Regulating Intestinal Microbiota.

Authors:  Hongyu Zhao; Rufeng Chen; Dongxue Zheng; Feng Xiong; Fan Jia; Jinyuan Liu; Lili Zhang; Nana Zhang; Shiqin Zhu; Yongmei Liu; Linhua Zhao; Xinmin Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-05-10       Impact factor: 6.073

3.  Proteomic Analysis of Human Follicular Fluid Reveals the Pharmacological Mechanisms of the Chinese Patent Drug Kunling Pill for Improving Diminished Ovarian Reserve.

Authors:  Haiyan Wang; Dan Cao; Meixian Wang; Yanbin Shi; Bowen Wei; Shiyuan Jiang; Yangyu Jiang; Hui Lian; Xiaoou Xue; Zhiqiang Ma; Jian Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-28       Impact factor: 2.650

4.  Quantitative Proteomics Reveals That a Prognostic Signature of the Endometrium of the Polycystic Ovary Syndrome Women Based on Ferroptosis Proteins.

Authors:  Jian Zhang; Nan Ding; Wenhu Xin; Xin Yang; Fang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

5.  Exploration of hub genes involved in PCOS using biological informatics methods.

Authors:  Fei Zhou; Yuling Xing; Tiantian Cheng; Linlin Yang; Huijuan Ma
Journal:  Medicine (Baltimore)       Date:  2022-10-07       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.